Feasibility and safety of adoptive immunotherapy with CIK cells after cord blood transplantation.
Five patients with aggressive acute leukemias who had relapsed after cord blood transplantation were treated with cord blood derived cytokine-induced killer (CIK) cells. These were obtained by ex vivo expansion, using as starting material the washouts of the cord blood units, left over at the end of the transplant. We did not observe any acute or delayed adverse event, and observed 1 partial response in 1 patient concomitantly with the development of acute grade III graft-versus-host disease (GVHD). These observations show the relatively low toxicity of cord blood-derived CIK cells and, more importantly, the feasibility of this immunotherapy program for patients who could not otherwise benefit from donor lymphocyte infusions.
Introna
Martino
M
USC Hematology, Ospedali Riuniti Bergamo, Italy. mintrona@ospedaliriuniti.bergamo.it
Pievani
Alice
A
Borleri
Gianmaria
G
Capelli
Chiara
C
Algarotti
Alessandra
A
Micò
Caterina
C
Grassi
Anna
A
Oldani
Elena
E
Golay
Josée
J
Rambaldi
Alessandro
A
D000293:Adolescent; D000328:Adult; D036101:Cord Blood Stem Cell Transplantation; D055612:Cytokine-Induced Killer Cells / Q000166:cytology / Q000276:immunology / Q000637:transplantation*; D003601:Cytotoxicity Tests, Immunologic; D005260:Female; D005312:Fetal Blood / Q000166:cytology; D006086:Graft vs Host Disease / Q000188:drug therapy / Q000453:epidemiology; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000009:adverse effects* / Q000379:methods*; D020014:K562 Cells; D007938:Leukemia / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D008297:Male; D045164:Mesenchymal Stem Cell Transplantation; D008875:Middle Aged; D012008:Recurrence; D016019:Survival Analysis; D016896:Treatment Outcome